Internal Medicine, Infectious Disease · Ocala, FL
NPI
1649289059
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
3306 SW 26th Ave, Suite 104
Ocala, FL, 34471
Phone (352) 622-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$507K
976,425 services
Medicare patients, 2024
794
Average age 76
Drug cost, 2024
$2.8M
1,874 prescriptions
Company payments, 2025
$2,068
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ivan Soosaipillai was code J0878 (injection, daptomycin, 1 mg), 939,996 times for 50 patients. In total Ivan Soosaipillai billed 976,425 services in 42 codes, and Medicare paid $507K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0878 Injection, daptomycin, 1 mg | Office | 939,996 | 50 | $0.04 | $39K |
| J0692 Injection, cefepime hydrochloride, 500 mg | Office | 7,844 | 50 | $0.99 | $7,741 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 5,642 | 96 | $0.52 | $2,916 |
| 96365 Intravenous Infusion, Hydration | Office | 2,742 | 97 | $46.65 | $128K |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 2,088 | 16 | $0.36 | $747 |
| J3370 Injection, vancomycin hcl, 500 mg | Office | 1,991 | 17 | $1.83 | $3,637 |
| 96367 Intravenous Infusion, Hydration | Office | 1,572 | 50 | $21.06 | $33K |
| 99232 Hospital E&M - Subsequent | Facility | 1,275 | 348 | $60.97 | $78K |
| 99214 Office E&M - Established | Office | 547 | 288 | $97.10 | $53K |
| 96366 Intravenous Infusion, Hydration | Office | 501 | 18 | $15.35 | $7,691 |
| 99233 Hospital E&M - Subsequent | Facility | 382 | 218 | $91.85 | $35K |
| 99222 Hospital E&M - Initial | Facility | 351 | 307 | $101.49 | $36K |
| 36415 Venipuncture Blood Collection | Office | 241 | 50 | $5.88 | $1,417 |
| 99223 Hospital E&M - Initial | Facility | 240 | 222 | $134.45 | $32K |
| 99214 Office E&M - Established | Facility | 163 | 25 | $72.32 | $12K |
By year: 2022 $577K for 510,589 services; 2023 $570K for 598,274 services; 2024 $507K for 976,425 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 241 | 50 | $5.88 | $1,417 |
Medicare prescription drug claims, 2024
In 2024, the drug Ivan Soosaipillai prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 246 prescriptions and refills. In total Ivan Soosaipillai wrote 1,874 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 246 | 260 | 29 | $933K |
| Cefepime Hcl Generic | 151 | 151 | 46 | $23K |
| Doxycycline Hyclate Generic | 121 | 207 | 66 | $2,695 |
| Vancomycin Hcl Generic | 104 | 104 | 39 | $19K |
| Daptomycin Generic | 84 | 84 | 24 | $96K |
| Juluca Dolutegravir/Rilpivirine | 79 | 79 | Under 11 | $253K |
| Cefaclor Generic | 79 | 197 | 31 | $8,707 |
| Clarithromycin Generic | 62 | 103 | 18 | $8,972 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 58 | 64 | Under 11 | $247K |
| Rifampin Generic | 55 | 106 | 19 | $3,849 |
| Descovy Emtricitabine/Tenofov Alafenam | 50 | 50 | Under 11 | $100K |
| Ciprofloxacin Hcl Generic | 46 | 78 | 30 | $682 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 45 | 49 | Under 11 | $219K |
| Ceftriaxone Ceftriaxone Sodium | 44 | 44 | 13 | $3,152 |
| Tivicay Dolutegravir Sodium | 42 | 42 | Under 11 | $79K |
Brand drugs: 744 claims; generic drugs: 1,130 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ivan Soosaipillai $2,068 ($2,068 in general payments such as food, travel and fees) from 8 companies. The largest payer was ViiV Healthcare Company with $672.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.